Active-ingredient Dossier

Ranibizumab

Active-ingredient Dossier for Ranibizumab (monoclonal antibody). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.

Brand: LUCENTIS
Brand: RANIVIZ
Brand: BYOOVIZ
Therapeutic area: Ophthalmology

What is

Ranibizumab Ranibizumab is a monoclonal antibody active ingredient.

Australian brands containing

Ranibizumab — LUCENTIS — RANIVIZ — BYOOVIZ

Therapeutic areas

Ranibizumab is registered in ophthalmology, with three brands containing this ingredient on the ARTG.

Sponsor landscape

Three sponsors market ranibizumab in Australia: Samsung Bioepis AU, Novartis Pharmaceuticals, and Actor Pharmaceuticals.

PBS and regulatory activity

One brand containing ranibizumab has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2023–24 financial year, PBS expenditure for ranibizumab was $92,576,340.45 across 108,632 scripts. The latest PBAC outcome was recorded on 1 May 2025, with two brands having PBAC outcomes on record. The latest AusPAR was published on 12 December 2023, with three brands having AusPARs on record.